BCAX - CIK 0002023658
The table below shows Bicara Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 |
|---|---|---|---|
| Operating cash flow | -$37.51M | -$28.11M | -$14.59M |
| Capital expenditure | $60.00K | $0.00 | $4.00K |
| Investing cash flow | $100.94M | $0.00 | $58.00K |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $163.34M | $460.00K | $137.00K |
Bicara Therapeutics Inc. reported operating cash flow of -$106.83M for fiscal year 2025. That is down 42.9% from -$74.75M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.